Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) dropped 3.1% during trading on Friday . The company traded as low as $1.72 and last traded at $1.72. Approximately 2,213 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 13,160 shares. The stock had previously closed at $1.78.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Adlai Nortye in a report on Saturday, September 27th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Adlai Nortye has a consensus rating of "Reduce" and a consensus target price of $9.00.
Read Our Latest Stock Analysis on ANL
Adlai Nortye Stock Down 3.1%
The business has a 50 day moving average price of $1.68 and a 200 day moving average price of $1.76.
About Adlai Nortye
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
